We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
UK-based biotechnology firm Tiziana Life Sciences has executed an agreement with STC Biologics for the manufacture of TZLS-501 for clinical studies in Covid-19 patients.
STC Biologics has completed construction of a single-use mammalian GMP manufacturing facility in Newton, MA, and has successfully conducted its first MCB and three GMP drug substance production runs.